Faster global financial news!
Biotechnology
-
Hyosung TNC begins commercial production at $1 billion bio-BDO plant in Vietnam
South Korean spandex maker Hyosung TNC has commenced commercial production at its $1 billion bio-BDO plant in Ho Chi Minh City, Vietnam. The plant has an annual production capacity of 50,000 tons, wit
-
OpenAI and Ginkgo Bioworks have significantly revamped their protein design competition format, shifting from a "human-AI showdown" to a "collaborative competition" to ease tensions within the scientific community regarding AI.
Ginkgo Bioworks originally planned for Stanford University Professor Michael Jewett to single-handedly take on OpenAI's AI agent team in a protein design competition. However, on the eve of the first
-
Korean biotech Alteogen files international patent for long-acting obesity drug platform
Alteogen, a Korean biotech company specializing in drug-delivery platform technologies, has filed an international patent application for its long-acting conjugate technology, which aims to prolong dr
-
BioNTech's lung cancer drug gotistobart shows significant overall survival benefit in Phase 3 trial
BioNTech (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial for patients with meta
-
Hong Kong Financial Secretary Paul Chan Says City Ready to Be Biotech Bridge Connecting Global Capital with Chinese Innovation
Financial Secretary Paul Chan stated in an address to the Biotechnology Investment Forum of BIOHK2026 on Thursday that Hong Kong is poised to be the "partner of choice" for linking global capital with
-
Jim Cramer calls surging biotech stock Nuvation Bio (NUVB) a "pure spec" despite analysts seeing 113% upside
Jim Cramer, during a September 3 episode of CNBC's Mad Money, labeled Nuvation Bio (NUVB) as "pure speculation," warning that its value primarily rests on potential future drug performance rather than
-
Analysis shows Johnson & Johnson's latest 13F filing reveals holdings in 15 biotech stocks, with Protagonist Therapeutics being the largest investment, whose stock price has surged 65% year-to-date.
According to Yahoo Finance analysis, Johnson & Johnson's latest 13F filing (as of June 30, 2026) disclosed its holdings of 15 stocks in the biotechnology and medical technology sectors. The analysis i
-
SBIO Token Analysis: Vector Space Biosciences' Digital Equity Token and Its Market Status
SBIO is an ERC-20 token issued by Vector Space Biosciences, intended to represent equity in the company and currently undergoing the U.S. Securities and Exchange Commission (SEC) registration process as a security. The project focuses on developing precision medicine solutions to address the stresses of space flight and diseases affecting all humanity, integrating bioscience, hardware, and AI technologies. Despite its ambitious vision, SBIO faces challenges in the market, including inconsistent data and extremely low liquidity, with 24-hour trading volumes appearing as zero or very low on some platforms, and significant discrepancies in market capitalization data. Investors are advised to exercise caution.
-
Billionaire investor Stanley Druckenmiller's family office increased its stake in Revolution Medicines (RVMD) by 26.5% in the second quarter of 2026.
Druckenmiller's Duquesne Family Office previously initiated a position in Revolution Medicines in the first quarter of 2026. Although Wall Street analysts only expect the biotech company's stock price
-
Billionaire Stanley Druckenmiller's Duquesne Family Office initiated a position in Rhythm Pharmaceuticals in the second quarter, betting on its rare obesity drug market.
Rhythm Pharmaceuticals (RYTM) focuses on treating rare forms of obesity caused by genetic disorders or damage to brain regions controlling hunger, a niche market currently untouched by giants like Eli
-
Axsome Therapeutics (AXSM) is up 16% year-to-date, with an average Wall Street price target of $285.42, implying an upside of approximately 37%.
Biotechnology company Axsome Therapeutics (NASDAQ: AXSM) has performed well this year, with its stock price up 16% year-to-date, outperforming the S&P 500's 11% gain. Wall Street analysts are optimist
-
Analysis suggests that the State Street SPDR S&P Biotech ETF (XBI) is poised to outperform the iShares Global Healthcare ETF (IXJ) in 2026.
The analysis points out that while the iShares Global Healthcare ETF (IXJ) has performed better over the past five years, the State Street SPDR S&P Biotech ETF (XBI) has outperformed IXJ year-to-date,
-
Claude AI Adds Biotech Pharvaris (PHVS) and AI Chipmaker Micron Technology (MU) to Portfolio, Both Also Hedge Fund Favorites
Claude AI recently added Pharvaris NV (NASDAQ: PHVS) with a 4% position and Micron Technology Inc (NASDAQ: MU) with a 6% position to its simulated portfolio. Pharvaris, a biotech company, has a key dr
-
Goldman Sachs-backed biotech firm Attovia raises $289 million in US IPO
Attovia Therapeutics Inc. is an early-stage drug developer focused on immune system disorders. Its initial public offering (IPO) priced at the top of its marketed range.
-
Braveheart, a biotech company backed by a16z, is seeking to raise $318.8 million through a U.S. IPO
Braveheart Bio Inc., a clinical-stage biopharmaceutical company backed by a16z, is seeking to raise up to $318.8 million through an initial public offering (IPO). This move will make it part of the gr
-
What is BIOB? How is the BIOB token?
In the cryptocurrency space, information regarding the token with the ticker symbol “BIOB” is relatively complex, as it may refer to several different projects or concepts. At present, there are two main possibilities: one is a cryptocurrency associated with the “Bio Protocol” project, and the other may be confused with the stock ticker symbol for “Bio-Rad Laboratories Class B.” This article will examine both scenarios separately and analyze their respective characteristics and market performance.
-
Hyosung TNC begins commercial production at $1 billion bio-BDO plant in Vietnam
South Korean spandex maker Hyosung TNC has commenced commercial production at its $1 billion bio-BDO plant in Ho Chi Minh City, Vietnam. The plant has an annual production capacity of 50,000 tons, wit
-
OpenAI and Ginkgo Bioworks have significantly revamped their protein design competition format, shifting from a "human-AI showdown" to a "collaborative competition" to ease tensions within the scientific community regarding AI.
Ginkgo Bioworks originally planned for Stanford University Professor Michael Jewett to single-handedly take on OpenAI's AI agent team in a protein design competition. However, on the eve of the first
-
Korean biotech Alteogen files international patent for long-acting obesity drug platform
Alteogen, a Korean biotech company specializing in drug-delivery platform technologies, has filed an international patent application for its long-acting conjugate technology, which aims to prolong dr
-
BioNTech's lung cancer drug gotistobart shows significant overall survival benefit in Phase 3 trial
BioNTech (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial for patients with meta
-
Hong Kong Financial Secretary Paul Chan Says City Ready to Be Biotech Bridge Connecting Global Capital with Chinese Innovation
Financial Secretary Paul Chan stated in an address to the Biotechnology Investment Forum of BIOHK2026 on Thursday that Hong Kong is poised to be the "partner of choice" for linking global capital with
-
Jim Cramer calls surging biotech stock Nuvation Bio (NUVB) a "pure spec" despite analysts seeing 113% upside
Jim Cramer, during a September 3 episode of CNBC's Mad Money, labeled Nuvation Bio (NUVB) as "pure speculation," warning that its value primarily rests on potential future drug performance rather than
-
Analysis shows Johnson & Johnson's latest 13F filing reveals holdings in 15 biotech stocks, with Protagonist Therapeutics being the largest investment, whose stock price has surged 65% year-to-date.
According to Yahoo Finance analysis, Johnson & Johnson's latest 13F filing (as of June 30, 2026) disclosed its holdings of 15 stocks in the biotechnology and medical technology sectors. The analysis i
-
Billionaire investor Stanley Druckenmiller's family office increased its stake in Revolution Medicines (RVMD) by 26.5% in the second quarter of 2026.
Druckenmiller's Duquesne Family Office previously initiated a position in Revolution Medicines in the first quarter of 2026. Although Wall Street analysts only expect the biotech company's stock price
-
Billionaire Stanley Druckenmiller's Duquesne Family Office initiated a position in Rhythm Pharmaceuticals in the second quarter, betting on its rare obesity drug market.
Rhythm Pharmaceuticals (RYTM) focuses on treating rare forms of obesity caused by genetic disorders or damage to brain regions controlling hunger, a niche market currently untouched by giants like Eli
-
Axsome Therapeutics (AXSM) is up 16% year-to-date, with an average Wall Street price target of $285.42, implying an upside of approximately 37%.
Biotechnology company Axsome Therapeutics (NASDAQ: AXSM) has performed well this year, with its stock price up 16% year-to-date, outperforming the S&P 500's 11% gain. Wall Street analysts are optimist
-
Analysis suggests that the State Street SPDR S&P Biotech ETF (XBI) is poised to outperform the iShares Global Healthcare ETF (IXJ) in 2026.
The analysis points out that while the iShares Global Healthcare ETF (IXJ) has performed better over the past five years, the State Street SPDR S&P Biotech ETF (XBI) has outperformed IXJ year-to-date,
-
Claude AI Adds Biotech Pharvaris (PHVS) and AI Chipmaker Micron Technology (MU) to Portfolio, Both Also Hedge Fund Favorites
Claude AI recently added Pharvaris NV (NASDAQ: PHVS) with a 4% position and Micron Technology Inc (NASDAQ: MU) with a 6% position to its simulated portfolio. Pharvaris, a biotech company, has a key dr
-
Goldman Sachs-backed biotech firm Attovia raises $289 million in US IPO
Attovia Therapeutics Inc. is an early-stage drug developer focused on immune system disorders. Its initial public offering (IPO) priced at the top of its marketed range.
-
Braveheart, a biotech company backed by a16z, is seeking to raise $318.8 million through a U.S. IPO
Braveheart Bio Inc., a clinical-stage biopharmaceutical company backed by a16z, is seeking to raise up to $318.8 million through an initial public offering (IPO). This move will make it part of the gr
-
SBIO Token Analysis: Vector Space Biosciences' Digital Equity Token and Its Market Status
SBIO is an ERC-20 token issued by Vector Space Biosciences, intended to represent equity in the company and currently undergoing the U.S. Securities and Exchange Commission (SEC) registration process as a security. The project focuses on developing precision medicine solutions to address the stresses of space flight and diseases affecting all humanity, integrating bioscience, hardware, and AI technologies. Despite its ambitious vision, SBIO faces challenges in the market, including inconsistent data and extremely low liquidity, with 24-hour trading volumes appearing as zero or very low on some platforms, and significant discrepancies in market capitalization data. Investors are advised to exercise caution.
-
What is BIOB? How is the BIOB token?
In the cryptocurrency space, information regarding the token with the ticker symbol “BIOB” is relatively complex, as it may refer to several different projects or concepts. At present, there are two main possibilities: one is a cryptocurrency associated with the “Bio Protocol” project, and the other may be confused with the stock ticker symbol for “Bio-Rad Laboratories Class B.” This article will examine both scenarios separately and analyze their respective characteristics and market performance.
Biotechnology
24H Trending
-
1
EU trade chief holds talks in China amid trade tensions, EU Parliament votes for tougher stance
-
2
FINO Coin Market Analysis: Trading Activity and Potential Risks
-
3
BitMart Exchange Has Ceased Operations: A Review of Perpetual Contract Services and Platform Status
-
4
Polkadot (DOT) Ecosystem Expansion: New Projects, Core Upgrades, and Tokenomics Transformation
-
5
TXBIT Coin Status Analysis: Token Market and Risks After the Closure of the Original Txbit Exchange
-
6
Overview of Cryptocurrency Exchanges Supporting USDT Stablecoin
-
7
China's Cryptocurrency Regulatory Policies and a Global Overview of Trading Platforms
-
8
Casper (CSPR) Token Analysis: The State of Enterprise Blockchains and Market Considerations
-
9
AI Debt Frenzy Triggers Credit Market Alarm: SpaceX Seeks $40 Billion in Funding, 10-Year US Treasury Yield Surpasses 5.3% to Hit New High Since 2002
-
10
DCR Coin: Decred Token Trading Platforms and Purchase Guide
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
